Seeking Alpha

Daiichi Sankyo's edoxaban holds its own in clinical testing

  • Daiichi Sankyo's (DSKYF) edoxaban again proves comparable to warfarin in late stage clinicals.
  • In a study of patients with A-fib, 1.5% of those given warfarin experienced a stroke versus 1.18% of those given the highest dose of edoxaban and 1.6% of those given the lower dose.
  • Bleeding was less common in those given edoxaban.
  • There were also fewer deaths among edoxaban patients.
  • Despite the data, some say there isn't enough evidence to warrant wholesale adoption: "The absolute risk reduction is small," a professor at McMaster University’s Department of Medicine tells Bloomberg.
  • Competitors: PFE and BMY's Eliquis and JNJ's Xarelto.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector